| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1973) Withdrawn (1980) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | N05CA01 |
| UNII: | I4744080IR |
| InChI Key | WEXRUCMBJFQVBZ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H18N2O3 |
| Molecular Weight | 226.28 |
| AlogP | 1.18 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 75.27 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 16.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
GABA-A receptor
|
50000 | 1700-40000 | - | - | - | |
|
Ion channel
Voltage-gated ion channel
Potassium channels
Two-pore domain potassium channel
|
- | - | - | - | 4 | |
|
Ion channel
Voltage-gated ion channel
Voltage-gated sodium channel
|
- | - | - | - | 1-8 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 94 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Status Epilepticus | 3 | D013226 | ClinicalTrials |
| Brain Injuries | 3 | D001930 | ClinicalTrials |
| Heart Diseases | 1 | D006331 | ClinicalTrials |
| Substance-Related Disorders | 1 | D019966 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 76-74-4 |
| ChEBI | 7983 |
| ChEMBL | CHEMBL448 |
| DrugBank | DB00312 |
| DrugCentral | 2095 |
| EPA CompTox | DTXSID7023435 |
| FDA SRS | I4744080IR |
| Human Metabolome Database | HMDB0014457 |
| Guide to Pharmacology | 5480 |
| KEGG | C07422 |
| PharmGKB | PA450859 |
| PubChem | 4737 |
| SureChEMBL | SCHEMBL24966 |
| ZINC | ZINC00004840 |